SCHEMBL623280

SCHEMBL623280

NC(C(=O)O)C1CCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 11/20 0.53
GRM2 Q14416 2/20 0.47
SLC1A2 P43004 2/20 0.46
SLC1A1 P43005 2/20 0.46
EPHX1 P07099 2/20 0.46
DPP7 Q9UHL4 3/20 0.44
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
GRM8 O00222 1/20 0.43
GRM6 O15303 1/20 0.43
LMNA P02545 1/20 0.43
APEX1 P27695 1/20 0.43
GRM5 P41594 1/20 0.43
PMP22 Q01453 1/20 0.43
GRM1 Q13255 1/20 0.43
GRM3 Q14832 1/20 0.43
GRM4 Q14833 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL919635 1.00 DPP4 (0.53) DPP4GRM2SLC1A2SLC1A1EPHX1
SCHEMBL1053865 1.00 DPP4 (0.53) DPP4GRM2SLC1A2SLC1A1EPHX1
SCHEMBL21969684 0.97 DPP4 (0.57) DPP4GRM2SLC1A2SLC1A1EPHX1
SCHEMBL16640290 0.97 DPP4 (0.57) DPP4GRM2SLC1A2SLC1A1EPHX1
SCHEMBL7868412 0.97 DPP4 (0.57) DPP4GRM2SLC1A2SLC1A1EPHX1
SCHEMBL24316913 0.97 DPP4 (0.57) DPP4GRM2SLC1A2SLC1A1EPHX1
SCHEMBL21977981 0.97 DPP4 (0.57) DPP4GRM2SLC1A2SLC1A1EPHX1
SCHEMBL21981265 0.97 DPP4 (0.57) DPP4GRM2SLC1A2SLC1A1EPHX1
SCHEMBL20819999 0.97 DPP4 (0.57) DPP4GRM2SLC1A2SLC1A1EPHX1
Cyclohexylglycyl SCHEMBL122348 0.97 DPP4 (0.57) DPP4GRM2SLC1A2SLC1A1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195702-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2025-06-19 US claimed
WO-2025054727-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS PROVINCIAL HEALTH SERVICES AUTHORITY (CA) 2025-03-20 WO claimed
US-20250059235-A1 CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME UNIV DREXEL (US) 2025-02-20 US claimed
EP-4499663-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS Provincial Health Services Authority (CA) 2025-02-05 EP claimed
CN-119213011-A Radiolabeled compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders 省卫生服务机构 2024-12-27 CN claimed
CN-119158034-A Bicyclic peptide ligands specific for conjugated protein-4 拜斯科技术开发有限公司 2024-12-20 CN claimed
CN-118406439-B Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing 万华化学集团电子材料有限公司 2024-10-18 CN claimed
CN-118510522-A Conjugated oligonucleotides and uses thereof IONIS制药公司 2024-08-16 CN claimed
CN-118406439-A Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing 万华化学集团电子材料有限公司 2024-07-30 CN claimed
US-20240123099-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2024-04-18 US claimed
EP-0642531-B1 MONOMER AND DIMER PEPTIDES, UTILIZATION AS CYTOPROTECTOR AGENTS AND PREPARATION METHOD INST VAISSEAUX ET DU SANG (FR) 1997-03-26 EP claimed
EP-0714909-A1 Composition for prophylaxis or treatment of pulmonary circulatory diseases Takeda Chemical Industries, Ltd. (JP) 1996-06-05 EP claimed
WO-1995024422-A1 BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES CORTECH, INC. (US) 1995-09-14 WO claimed
EP-0647449-A1 Sustained-release preparation of anti-endothelin substance Takeda Chemical Industries, Ltd. (JP) 1995-04-12 EP claimed
EP-0642531-A1 MONOMER AND DIMER PEPTIDES, UTILIZATION AS CYTOPROTECTOR AGENTS AND PREPARATION METHOD. SERBIO (FR) 1995-03-15 EP claimed
EP-0620008-A1 Use of vip, analogues and fragments thereof for the treatment of neurodegenerative diseases YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD. (IL) 1994-10-19 EP claimed
WO-1993023426-A1 MONOMER AND DIMER PEPTIDES, UTILIZATION AS CYTOPROTECTOR AGENTS AND PREPARATION METHOD SERBIO (FR) 1993-11-25 WO claimed
EP-0373549-B1 AMINO ACID DERIVATIVES WITH ENZYME-INHIBITING PROPERTIES, PROCESS TO SYNTHETISE THEM, COMPOSITION CONTAINING THEM AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1993-09-01 EP claimed
EP-0211744-B1 PEPTIDIC AMINO-ALCOHOL DERIVATIVES CONTAINING A TETRA-SUBSTITUTED CARBON ATOM, INHIBITORS OF RENIN AND OF ACID PROTEASES, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS SANOFI (FR) 1991-12-04 EP claimed
EP-0100053-B1 COMPOUNDS HAVING ANGIOTENSIN CONVERTING ENZYME INHIBITORY ACTIVITY AND DIURETIC ACTIVITY RORER INTERNATIONAL (OVERSEAS) INC. (US) 1987-10-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059235-A1 CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME ZC3HAV1, VIP, LNPEP DPP4 44/4885GRM2 4242/4885SLC1A2 4502/4885
US-20240123099-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS GRPR, NPY5R, NPY2R DPP4 220/4885GRM2 261/4885SLC1A2 298/4885
US-20250195702-A1 RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS GRPR, NPY5R, NPY2R DPP4 198/4885GRM2 288/4885SLC1A2 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.